Adoptive therapy with T cell receptor (TCR)-engineered T cells has shown promising results in the treatment of patients with tumors, and the number of TCRs amenable for clinical testing is expanding rapidly. Notably, adoptive therapy with T cells is challenged by treatment-related side effects, which calls for cautious selection of target antigens and TCRs that goes beyond their mere ability to induce high T cell reactivity. Here, we propose a sequence of in vitro assays to improve selection of TCRs, and exemplify risk assessments of on-target as well as off-target toxicities using TCRs directed against Cancer Germline Antigens. The proposed panel of assays covers parameters considered key to safety, such as expression of target antigen in healthy tissues, determination of a TCR's recognition motif towards its cognate peptide, and TCR's cross-reactivity towards non-cognate peptides.
Introduction
Therapeutic use of anti-tumor T cells has proven feasible in a multitude of trials over the last decade. Alongside the demonstration of clinical benefit and enthusiasm about the therapeutic efficacy, the occurrence of toxicities has stimulated awareness of safety pitfalls. While initial studies demonstrated recognition, and sometimes destruction of healthy tissues (1) (2) (3) , later studies demonstrated lethal adverse effects in individual patients (4, 5) . These studies highlight the two main challenges facing safety of T cell receptor (TCR) gene therapy: on-and off-target toxicities. With a quickly expanding panel of TCRs that have generally been selected for their ability to provide T cells with high avidities towards tumor antigens, there is an urgent need for streamlining the safety assessment of these TCRs prior to clinical usage.
Selecting target antigens
An ideal target antigen for adoptive T cell therapy (AT) displays two important features: it is immunogenic and shows selective and homogenous expression in tumor tissue. Immunogenicity is best explained as an antigen's ability to be recognized by and sufficiently activate T cells, a feature that is generally well addressed when selecting a target antigen and its corresponding TCR (reviewed in (6) ). In example, characteristics related to the immunogenicity of two MAGE-C2 (MC2) antigen epitopes are summarized in Table I . Selective expression in tumor tissue, and hence its absence in healthy tissues, would reduce the risk for on-target toxicities.
Differentiation, over-expressed or onco-fetal antigens are not absent from healthy tissues and the targeting of these antigens, e.g. MART-1 or carcinoembryonic antigen (CEA), by TCRtransduced T cells has resulted in severe destruction of melanocytes in the eyes, ears and skin (1) or inflammation of the colon (2, 3) . Candidate antigens that are exclusively expressed by tumor tissues include neo-antigens and oncoviral antigens. Neo-antigens are derived from somatic DNA alterations and their identification requires analyses of mutations, gene expression, and algorithms that predict antigen processing and presentation by major histocompatibility complex (MHC) (7) (8) (9) . AT studies with tumor infiltrating lymphocytes (TILs) in patients with melanoma and cholangiocarcinoma showed that clinical benefit was associated with T cell responses against neo-antigens (9-11). Current exploitation of neo-antigens in AT, however, is challenged by the uncertainty of current algorithms accurately predicting immunogenicity, and the fact that neo-antigens are usually specific per patient (12) (13) (14) . Viral antigens are present in more than 10% of human cancers and are often the result of viral insertion into the genome and subsequent reactivation in tumors. AT studies using TILs reactive against either HPV or EBV have shown clinical successes in patients with cervical cancer or nasopharyngeal carcinoma, respectively (15, 16) . In addition to neo-antigens and onco-viral antigens, also certain cancer germline antigens (CGAs) demonstrate tumor-selective expression. In fact, CGAs are expressed in gonadal tissues and some in thymus (17) , and certain CGAs are considered to be selectively derepressed in tumor tissuess (for detailed reviews, see (6, 18, 19) ). MAGE-A3 and NY-ESO1 are examples of CGAs that have already been targeted by TCR-engineered T cells in patients with metastatic melanoma, metastatic synovial sarcoma or multiple myeloma (4, 20) . Although offtarget toxicities were observed with the targeting of the former antigen (most likely an issue of the TCRs; see next section), the safe use of selected CGAs was suggested by the targeting of NY-ESO1 demonstrating clinical benefit without toxicities (20, 21) .
We recommend for any antigen, with the exception of neo-antigens, to test the antigen's absence from a large panel of healthy organs. Online databases such as the protein atlas (http://www.proteinatlas.org/) or the CGA database (www.cta.lncc.br) combine extensive data from transcriptomic analyses and antibody stainings from numerous normal, non-cancerous cell lines and tissues. When applying these tools to assess the expression of MC2, we observed that mRNA expression is restricted to cells from cancers and testes, the latter considered to possess an immune privileged status (no MHC expression; thus no detection by T cells). The use of commercially available cDNA libraries of a large series of healthy tissues enable researchers to extend online analyses and quantify antigen expression with a laboratory assay. When performing qPCR using such a cDNA library, we demonstrated absence of MC2 mRNA in healthy tissues as illustrated in figure 1A . In case specific antibodies are available, we would recommend to follow-up qPCR with immune histochemistry. Using an MC2-specific antibody, we confirmed the presence of MC2 protein in testis and melanoma as well as its absence in multiple healthy tissues, such as brain, heart, intestine and lung (see figure 1B) . However, both qPCR and immune histochemistry cannot formally exclude the presence of rare antigen-positive cells within a tissue, e.g. stem cells. For example, mRNA of certain CGAs has been detected only in medullary thymic epithelial cells but not total thymus (17) . As an additional means to exclude target antigen expression, sophisticated in vitro cell cultures have been developed to closely mimic complete tissues or organs (commented in next section) (5, 22) .
Selecting therapeutic TCRs
Once the safety of the target antigen has been assessed, one can start selecting TCRs. Procedures to obtain tumor-reactive T cells and hence TCRs can generally be divided into those that rely on tolerant and those that rely on non-tolerant repertoires of T cells. Tolerant repertoires, where deletion of T cells with an avidity outside the thymic selection window has occurred, have been used to obtain T cell clones from patients following successful TIL therapy, peptide vaccination, or using in vitro pulsing of autologous dendritic cells (23, 24) . Notably, the thymic selection of T cells is most likely a trade-off between producing a self-tolerant yet sufficiently diverse and responsive TCR repertoire, and escape of self-reactive TCRs cannot be negated. Indeed, TCRs specific for over-expressed antigens and obtained from the native repertoire have been shown to initiate autoimmune side effects (1) . The use of non-tolerant repertoires, with the rationale of allowing the generation of high-avidity T cells, has been applied in allogeneic in vitro as well as in vivo systems. For example, HLA-mismatched antigen-presenting cells (25) or artificial antigen-presenting cells pulsed with peptides of interest facilitate the in vitro generation of tumor-reactive T cells (26) . In vivo, mice transgenic for human HLA as well as mice transgenic for human TCR and HLA-A2 genes (27) have been immunized and used as a source of TCRs.
After having obtained antigen-reactive T cells, sequences of the TCRα and β chains can be determined by molecular techniques such as 5′ RACE (23), enhanced PCR methods, capturing and indexing of genomic DNA-encoding TCR chains (28) , or sequencing and pairing of TCR chains based on combinatorial algorithms (29) .
It is important to note that TCRs derived from above-mentioned repertoires, in particular the non-tolerant repertoir, have not been selected in the presence of all patient MHC alleles and in the case of mice neither against human peptides present in the thymus, and may show allo-and non-cognate reactivity. Moreover, TCRs, even though obtained from highly tumor-reactive T cells, have an inherent degeneracy for peptide recognition and are able to recognize more than a single peptide. This dynamic flexibility in antigen recognition is in part accredited to the bending ability of the TCR-CDR domains (30, 31) , but also to the dominant interaction of the TCR with a restricted number and order of amino acids present in the MHC-presented peptide. To minimize the risk of selecting a TCR that recognizes non-cognate self-peptides, we recommend a series of assays that assess the risk of this so-called off-target toxicity. These assays are illustrated with two patient-derived MC2-specific TCRs 6 and 16 with details and evaluation of anti-tumor T cell responses mediated by TCR6 and TCR16 summarized in Table I .
Recognition of random epitopes
Initial assessment of a TCR's self-reactivity can be done by testing the responsiveness of TCRtransduced T cells towards random peptides known to be presented by the respective HLA restriction allele. Mathematical projections indicate that amongst a pool of ~10 12 peptides, a single TCR may react with >10 6 peptides, supporting the notion of TCR degeneracy for peptide recognition, which potentially contributes to a more diverse TCR repertoire (32). We co-cultured TCR6 and TCR16 T cells with antigen-presenting cells loaded with saturating concentrations of >100 common, HLA-A2-eluted self-peptides (4). As depicted in figure 2, both T cell populations mediated a T cell response to their respective cognate peptides, but to none of the other peptides.
Importantly, these data hint to lack of cross-reactivity of these two TCRs, but we cannot fully exclude recognition to random peptides. Another assessment of self-reactivity can be conducted by testing TCR-transduced T cells towards allogenic HLA molecules. In order to exclude activation of T cells upon recognition of foreign HLA molecules, panels of lymphoblastoid B cell lines with various HLA allotypes have proven valuable (33, 34) .
Recognition of cognate epitope via critical amino acids
Further assessment of a TCR's self-reactivity, and a key assay in this communication, is the testing of a TCR's intrinsic capacity to recognize peptides highly homologous to its cognate epitope (35, 36) . To this end, one can determine the recognition motif, i.e. the position and sequence of amino acids within the cognate epitope that are crucial for binding to the TCR. This motif is unique per TCR and can be considered a surrogate measure for the extent of crossreactivity of TCRs (22, 33) . The importance to assess such motifs became apparent from two recent clinical trials using AT with TCR-engineered T cells. The first trial targeting MAGE-A3
and A9 (MA3/9) in the context of HLA-A2 utilized the TCR 9W11 and reported neurological toxicities in two patients with metastatic melanoma (4). The second trial targeting MA3 in the context of HLA-A1 utilized the TCR a3a and reported cardiac toxicities in one patient with metastatic melanoma and one patient with multiple myeloma (5). Both TCRs were affinity enhanced in vitro and mediated toxicity by recognizing peptides highly similar to the cognate peptide, namely peptides derived from MAGE-A12 and Titin present in brain and heart tissue, respectively. These studies clearly underline the need to assess recognition motifs, and the search for T cell reactivities against homologous self-peptides, prior to clinical application. The importance of recognition motifs is timely and its assessment has only occurred for a limited number of TCRs to date, which is summarized in Table II .
Using a set of altered peptide ligands (APLs), peptides containing individual alanines replacements at every single position in the cognate peptide (in case of an endogenous alanine→glycine), we conducted stimulation assays with TCR6 and 16 T cells. Critical amino acids are defined as those that, when testing the respective APLs, result in a drop of the T cell response (generally using IFN production as a readout) of > 50% when compared to the response toward the cognate peptide. Following the determination of these motifs, as exemplified in figure 3A , we used ScanProSite (http://prosite.expasy.org/scanprosite/) (37) and identified target antigens, listed in figure 3B , that harbor the recognition motif and represent potential cross-reactive targets for TCRs 6 and 16. Subsequently, these self-peptides were tested for their ability to induce T cell responses towards HLA-A2-postive antigen presenting cells loaded with saturating concentrations (1µM) of peptide. These experiments yielded a short list of selfpeptides that are actually recognized by the TCRs under study, defined as those that resulted in at least a T cell IFNγ response > 2.5% of the response to cognate peptide (figure 3B: underlined antigens).
Recognition of non-cognate epitopes that contain recognition motif
Once self-peptides that can be recognized by TCR T cells have been identified, we recommend to execute two additional tests to more stringently assess the risk for self-reactivity. These tests MB4 showed expression within epididymis and vagina, whereas MC1 showed no expression in any of the healthy non-gonadal tissues. These data highlight the stringent safety profile of TCR16, the TCR selected for a clinical trial to treat melanoma and head-nand-neck carcinoma, currently prepared at Erasmus MC.
Future perspective of in vitro assays assessing risk of TCR-mediated toxicities
The proposed collection and sequence of in vitro assays to assess risks for toxicities are presented in figure 5 . We advocate this testing for TCRs with clinical intent, in particular those
TCRs reactive against a self-peptide and derived from a non-tolerant repertoire and/or following gene-enhancement. In extension to gene-enhancement, introduction of TCR-CDR mutations has been a commonly used tool to generate high-affinity TCRs (2, 4, 5, 20) . While such gene-enhanced TCRs recognize target peptides at increased affinities when compared to the corresponding wildtype TCRs, consequently such TCRs are also at risk to recognize non-cognate peptides. To test whether affinity enhancement led to an increase in degeneracy for peptide recognition, we made use of a panel of 8 TCRs specific for the same cognate peptide gp100 181-188 :HLA-A2) but harboring 2-3 mutated amino acids in either their CDR2β, CDR3α or CDR3β domains (Govers, Ms submitted). Upon assessment of the recognition motifs and search for motif-harboring selfpeptides, it became apparent that enhanced affinity was accompanied by drastic increase in the TCR's ability to recognize self-peptides (Table III) . These data extend earlier findings regarding a correlation between affinity enhancement and loss of TCR specificity (40) , and warrant caution when trying to change the TCR-CDR structure as it compromises the stringet recognition of cognate peptide (31, 41) .
Taken together, here we propose a platform of in vitro assays that in combination with available online-databases and tools allows for optimal toxicity risk-assessment for target antigens and IFNγ response to APLs is displayed as mean % relative to response to cognate peptides ± SEM (n=4). Responses < 50% (dashed line) were indicative of amino acids critical for TCR recognition (recognition motif: underlined amino acids). (B) Homologous motifs from (A) were queried against a human protein database using ScanProSite. This yielded 27 and 1 non-cognate matches for TCR6 and TCR16, respectively. Subsequently, TCR6 or TCR16 T cells were cocultured with T2 cells loaded with 1µM of these 27 and 1 peptide(s), and IFNγ levels were measured in 24h culture supernatants by ELISA (n=4). Underlined peptides induced a T cell 1090pg/ml 605pg/ml 835pg/ml 311pg/ml 292pg/ml 217pg/ml EB81-MEL: 518-A2: 607-B: SCC-9: 93-VU-120: SUM-195-PT: 1738pg/ml 461pg/ml 626pg/ml 207pg/ml 26pg/ml 466pg/ml a according to http://www.cbs.dtu.dk/services/NetCTLpan/. b T2 cells were pulsed with titrated amounts of ALK or LLF peptide and formation of pMHC class I complexes on the cell surface was quantified via flow cytometry using PE-labeled HLA-A2 mAb (23) . c cDNAs derived from patient-derived T cell clones were PCR amplified using either a set of TCR-Vα or Vβ sense primers and a corresponding TCR-Cα or Cβ antisense primer or 5'RACE (rapid amplification of cDNA ends). Following nested PCRs and cloning, TCRα and β sequences were identified using www.imgt.org and classified according to the Lefranc nomenclature (see (23) for details).
d TCR T cells were pulsed with titrated amounts of PE-labeled pMHC multimer, and binding was quantified via flow cytometry.
e TCR T cells were antigen-presenting cells that were pulsed with titrated amounts of cognate peptide, and functional T cell avidity was quantified via ELISA measurements of IFNγ production.
f TCR-transduced T cells were co-cultured with 3 melanoma, 2 head-and-neck carcinoma and 1 triple-negative breast cancer cell lines all positive for HLA-A2 and MC2 (determined by qPCR) at an E:T ratio of 3:1 for 24h. Cell lines were treated with epigenetic drugs Azacytidine and Valproate as well as IFNγ prior to co-culture (see (23) for details). IFNγ levels in 24h culture supernatants were measured by ELISA; displayed values are means of five experiments. Note that epigenetic drugs induce enhanced and tumor-selective expression of MC2 in vitro (23) as well as enhanced tumor immunogenicity in vivo (18) . n.d. = not determined. 
T1367 MAGE-A1 A2 KVLEYVIKV xxxEYxIKx 62 6 (33) s24-TCR survivin A2 ELTLGEFLKL xLTxGEFLKx 1 1 (44) gp100 wt gp100 A2 YLEPGPVTA xLEPGPxxA 4 4 Govers, Ms. submitted fl-MPD gp100 A2 YLEPGPVTA YxEPxxxxx >1000 >500 (45) fl-296 gp100 A2 YLEPGPVTA YxExxxxxx >1000 >500 (45) ) and a predicted affinity value of <10M for binding of the peptide to its respective MHC; affinity calculations according to NetMHCpan (http://www.cbs.dtu.dk/services/NetMHCpan/). 
